Iqtopam (Clonazepam)

Clonazepam enhances the activity of the inhibitory neurotransmitter gamma‑aminobutyric acid (GABA) by binding to the benzodiazepine site on GABA‑A receptors. This increases chloride ion flow into neurons, leading to hyperpolarisation and reduced neuronal excitability, which underpins its anticonvulsant and anxiolytic effects.

The appropriate dose of Iqtopam is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and response to therapy. Dosing regimens are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Safety data for clonazepam during pregnancy and lactation are limited. Clinicians must weigh potential benefits against possible risks to the fetus or infant. If treatment is considered essential, it should be prescribed by a specialist familiar with the maternal‑fetal risk profile.

To request Iqtopam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Compared with agents such as diazepam, clonazepam (Iqtopam) has a longer half‑life and higher potency for seizure control, making it useful for chronic epilepsy management. However, its sedative profile is similar, and drug‑interaction potential must be evaluated for each patient.

Iqtopam should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken. Keep the product in its original packaging until use and discard any solution that appears discoloured or contains particles.

Iqtopam is supplied as an injectable solution for intramuscular or intravenous injection. Administration is performed by qualified healthcare personnel using aseptic technique, with the dose and rate of infusion determined by the prescribing clinician.

Serious adverse events include respiratory depression, severe hypotension, Stevens‑Johnson syndrome, suicidal thoughts, anaphylactic reactions, and hepatic dysfunction. Patients should be monitored closely for signs of these conditions, especially when combined with other central nervous system depressants.

Iqtopam is contraindicated in individuals with known hypersensitivity to clonazepam or any component of the formulation, and in patients with severe acute narrow‑angle glaucoma. Caution is also advised for those with significant respiratory insufficiency, severe hepatic impairment, or a history of substance dependence.